Matthew J Walters

Summary

Publications

  1. ncbi CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens
    Matthew J Walters
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, United States Electronic address
    Immunol Lett 151:44-7. 2013
  2. ncbi Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    Matthew J Walters
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Pharmacol Exp Ther 335:61-9. 2010

Collaborators

Detail Information

Publications2

  1. ncbi CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens
    Matthew J Walters
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, United States Electronic address
    Immunol Lett 151:44-7. 2013
    ..These results highlight the inadequacy of genetic deletion of CCR9 when predicting the effects of pharmacological CCR9 inhibition on intestinal biology...
  2. ncbi Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    Matthew J Walters
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Pharmacol Exp Ther 335:61-9. 2010
    ..Analysis of the plasma level of drug associated with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation...